Single Versus Dual Antiplatelet Therapy After Coronary Artery Bypass Grafting for Unprotected Left-Main Coronary Disease
Authors: Daoulah Amin , Qenawi Wael , Alshehri Ali , Jameel Naser Maryam , Elmahrouk Youssef , Alshehri Mohammed , Elmahrouk Ahmed , Qutub Mohammed A. , Alzahrani Badr , Yousif Nooraldaem , Arafat Amr A. , Almahmeed Wael , Elganady Abdelmaksoud , Dahdouh Ziad , Hersi Ahmad S. , Jamjoom Ahmed , Alama Mohamed N. , Selim Ehab , Hashmani Shahrukh , Hassan Taher , Alqahtani Abdulrahman M. , Abohasan Abdulwali , Ghani Mohamed Ajaz , Al Nasser Faisal Omar M. , Refaat Wael , Iskandar Mina , Haider Omar , Fathey Hussien Adnan , Ghonim Ahmed A. , Shawky Abeer M. , Abualnaja Seraj , Kazim Hameedullah M. , Abdulhabeeb Ibrahim A. M. , Alshali Khalid Z. , Aithal Jairam , Altnji Issam , Amin Haitham , Ibrahim Ahmed M. , Al Garni Turki , Elkhereiji Abdulaziz A. , Noor Husam A. , Ahmad Osama , Alzahrani Faisal J. , Alasmari Abdulaziz , Alkaluf Abdulaziz , Elghaysha Ehab , Al Wabisi Salem Owaid , Algublan Adel N. , Nasim Naveen , Alhamid Sameer , Sait Basim , Alqahtani Abdulrahman H. , Balghith Mohammed , Kanbr Omar , Abozenah Mohammed , Lotfi Amir 
Published: February 2024

Background:

The use of dual antiplatelet therapy (DAPT) after coronary revascularization for left-main disease is still debated. The study aimed to characterize patients who received dual versus single antiplatelet therapy (SAPT) after coronary artery bypass grafting (CABG) for unprotected left-main disease and compare the outcomes of those patients.

Results:

This multicenter retrospective cohort study included 551 patients who were grouped into 2 groups: patients who received SAPT (n = 150) and those who received DAPT (n = 401). There were no differences in age (P = 0.451), gender (P = 0.063), smoking (P = 0.941), diabetes mellitus (P = 0.773), history of myocardial infarction (P = 0.709), chronic kidney disease (P = 0.615), atrial fibrillation (P = 0.306), or cerebrovascular accident (P = 0.550) between patients who received SAPT versus DAPT. DAPTs were more commonly used in patients with acute coronary syndrome [87 (58%) vs. 273 (68.08%); P = 0.027], after off-pump CABG [12 (8%) vs. 73 (18.2%); P = 0.003] and in patients with radial artery grafts [1 (0.67%) vs. 32 (7.98%); P < 0.001]. While SAPTs were more commonly used in patients with low ejection fraction [55 (36.67%) vs. 61 (15.21%); P < 0.001] and in patients with postoperative acute kidney injury [27 (18%) vs. 37 (9.23%); P = 0.004]. The attributed treatment effect of DAPT for follow-up major adverse cerebrovascular and cardiac events was not significantly different from that of SAPT [β, −2.08 (95% confidence interval (CI), −20.8–16.7); P = 0.828]. The attributed treatment effect of DAPT on follow-up all-cause mortality was not significantly different from that of SAPT [β, 4.12 (CI, −11.1–19.32); P = 0.595]. There was no difference in bleeding between groups (P = 0.666).

Conclusions:

DAPTs were more commonly used in patients with acute coronary syndrome, after off-pump CABG, and with radial artery grafts. SAPTs were more commonly used in patients with low ejection fraction and acute kidney injury. Patients on DAPT after CABG for left-main disease had comparable major adverse cerebrovascular and cardiac events and survival to patients on SAPT, with no difference in bleeding events.